Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced it was selected as a spoke for the
Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide
health innovation network launched by the Advanced Research
Projects Agency for Health (ARPA-H).
As an Investor Catalyst Hub spoke, Daré gains access to
potential funding and flexible contracting for faster award
execution compared to traditional government contracts. Spoke
membership also offers opportunities to provide input on ARPA-H
challenge areas and priorities, along with access to valuable
networking opportunities and a robust resource library.
“Earlier this year, I was honored to participate in the ARPA-H
event where First Lady Jill Biden and ARPA-H announced ARPA-H’s
Sprint for Women’s Health, an initiative intended to fundamentally
change the trajectory of women’s health care research and radically
accelerate the next generation of discoveries. We look
forward to the potential funding and ongoing opportunity to provide
input into the priority area of women’s health through our
selection as an Investor Catalyst Hub spoke,” said Sabrina Martucci
Johnson, President and Chief Executive Officer of Daré
Bioscience.
About the ARPA-H Investor Catalyst Hub and the Spoke
Network
Based in the Greater Boston area and managed by VentureWell, the
Investor Catalyst Hub seeks to accelerate the commercialization of
groundbreaking and accessible biomedical solutions. It utilizes an
innovative hub-and-spoke model designed to reach a wide range of
nonprofit organizations and Minority-Serving Institutions, with the
ultimate aim of delivering scalable healthcare outcomes for all
Americans.
The Investor Catalyst Hub Spoke Network is a dynamic nationwide
network of organizations aligned to ARPA-H’s overarching mission to
improve health outcomes through the following research focus areas:
health science futures, proactive health, scalable solutions, and
resilient systems. Investor Catalyst Hub spokes represent a broad
spectrum of expertise, geographic diversity, and community
perspectives.
The spoke network will continue to grow as the Investor Catalyst
Hub expands its efforts, with applications being selected on a
rolling basis. Interested organizations can visit
https://investorcatalysthub.org/ to learn more or submit a
membership application.
“Our spoke network embodies a rich and representative range of
perspectives and expertise,” said Mark Marino, Vice President of
Growth Strategy and Development for VentureWell and Project
Director for the Investor Catalyst Hub. “Our spokes comprise a
diverse network that will be instrumental in ensuring that
equitable health solutions reach communities across every state and
tribal nation.”
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to
advancing innovative products for women’s health. The company’s
mission is to identify, develop and bring to market a diverse
portfolio of differentiated therapies that prioritize women's
health and well-being, expand treatment options, and improve
outcomes, primarily in the areas of contraception, vaginal health,
reproductive health, menopause, sexual health and fertility.
The first FDA-approved product to emerge from Daré’s portfolio
of women’s health product candidates is XACIATO™ (clindamycin
phosphate) vaginal gel 2%, a lincosamide antibacterial indicated
for the treatment of bacterial vaginosis in female patients 12
years of age and older, which is under a global license agreement
with Organon. Organon commenced U.S. marketing of XACIATO in the
fourth quarter of 2023. Daré’s portfolio also includes potential
first-in-category candidates in clinical development: Ovaprene®, a
novel, hormone-free monthly intravaginal contraceptive whose U.S.
commercial rights are under a license agreement with Bayer;
Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil,
the active ingredient in Viagra®, to treat female sexual arousal
disorder (FSAD); and DARE-HRT1, a combination bio-identical
estradiol and progesterone intravaginal ring for menopausal hormone
therapy. To learn more about XACIATO, Daré’s full portfolio of
women’s health product candidates, and Daré’s mission to deliver
differentiated therapies for women, please visit
www.darebioscience.com.
Daré Bioscience leadership has been named on the Medicine
Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In
2023, Daré's CEO was honored as one of Fierce Pharma’s Most
Influential People in Biopharma for Daré’s contributions to
innovation and advocacy in the women’s health space. Daré
Bioscience placed #1 in the Small Company category of the San Diego
Business Journal’s 2023 Best Places to Work Awards.
Daré may announce material information about its finances,
product and product candidates, clinical trials and other matters
using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company and may also use
social media to communicate important information about the
company, its finances, product and product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these X (formerly Twitter) accounts: @SabrinaDareCEO
and @DareBioscience. Any updates to the list of social media
channels the company may use to communicate information will be
posted in the Investors section of Daré’s website.
Forward-Looking Statements
Daré cautions you that all statements, other than statements of
historical facts, contained in this press release, are
forward-looking statements. Forward-looking statements, in some
cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” “project,” “target,” “objective,” or the negative
version of these words and similar expressions. In this press
release, forward-looking statements include, but are not limited
to, statements relating to potential funding and other
opportunities and benefits for Daré as a result of spoke membership
in the Investor Catalyst Hub Spoke Network. In addition, as used in
this press release, the description of a product candidate as
“first-in-category” is a forward-looking statement relating to the
potential of the candidate to represent a new category of product
if it were to receive marketing approval for the indication for
which Daré is developing it. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause Daré’s actual results, performance or achievements to be
materially different from future results, performance or
achievements expressed or implied by the forward-looking statements
in this press release, including, without limitation, risks and
uncertainties related to: Daré’s ability to raise additional
capital when and as needed to advance its product candidates,
execute its business strategy and continue as a going concern;
Daré’s ability to develop, obtain FDA or foreign regulatory
approval for, and commercialize its product candidates and to do so
on communicated timelines; failure or delay in starting, conducting
and completing clinical trials of a product candidate; Daré’s
ability to design and conduct successful clinical trials, to enroll
a sufficient number of patients, to meet established clinical
endpoints, to avoid undesirable side effects and other safety
concerns, and to demonstrate sufficient safety and efficacy of its
product candidates; Daré’s dependence on third parties to conduct
clinical trials and manufacture and supply clinical trial material
and commercial product; the risk that positive findings in early
clinical and/or nonclinical studies of a product candidate may not
be predictive of success in subsequent clinical and/or nonclinical
studies of that candidate; the risk that the FDA, other regulatory
authorities, members of the scientific or medical communities or
investors may not accept or agree with Daré’s interpretation of or
conclusions regarding data from clinical studies of its product
candidates; the risk that development of a product candidate
requires more clinical or nonclinical studies than Daré
anticipates; the loss of, or inability to attract, key personnel;
the effects of macroeconomic conditions, geopolitical events,
public health emergencies, and major disruptions in government
operations on Daré’s operations, financial results and condition,
and ability to achieve current plans and objectives; the risk that
developments by competitors make Daré’s product or product
candidates less competitive or obsolete; difficulties establishing
and sustaining relationships with development and/or commercial
collaborators; failure of Daré’s product or product candidates, if
approved, to gain market acceptance or obtain adequate coverage or
reimbursement from third-party payers; Daré’s ability to retain its
licensed rights to develop and commercialize a product or product
candidate; Daré’s ability to satisfy the monetary obligations and
other requirements in connection with its exclusive, in-license
agreements covering the critical patents and related intellectual
property related to its product and product candidates; Daré’s
ability to adequately protect or enforce its, or its licensor’s,
intellectual property rights; the lack of patent protection for the
active ingredients in certain of Daré’s product candidates which
could expose its products to competition from other formulations
using the same active ingredients; product liability claims;
governmental investigations or actions relating to Daré’s product
or product candidates or the business activities of Daré, its
commercial collaborators or other third parties on which Daré
relies; the impact of pharmaceutical industry regulation and health
care legislation in the United States and internationally; global
trends toward health care cost containment; cybersecurity incidents
or similar events that compromise Daré’s technology systems or
those of third parties on which it relies and/or significantly
disrupt Daré’s business; and disputes or other developments
concerning Daré’s intellectual property rights. Daré’s
forward-looking statements are based upon its current expectations
and involve assumptions that may never materialize or may prove to
be incorrect. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. For a
detailed description of Daré’s risks and uncertainties, you are
encouraged to review its documents filed with the SEC including
Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date on which they were
made. Daré undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
Media and Investors on behalf of Daré Bioscience,
Inc:Camilla White / Simona KormanikovaDentons Global
AdvisorsDareBioscience@dentonsglobaladvisors.com /
1.212.466.6450
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2023 to Aug 2024